Designing Innovation Around Patient Access and Responsibility: Why Early Decisions Determine Who Gets Treated

Pharmaceutical innovation succeeds every day, yet patient access too often does not.

Regulatory approval is frequently treated as the finish line, but it only grants permission to market a therapy and does not guarantee that a single patient will receive it, because between approval and adoption lies a complex reality shaped by evidence, affordability, policy, and trust.

In Designing Pharmaceutical Innovation Around Patient Access and Responsibility, Tony Toks Akiwumi challenges the industry's most persistent assumption that good science naturally finds its way to patients, drawing on real world experience across development, market access, and policy to show how early decisions in trial design, evidence generation, pricing, and stakeholder engagement quietly determine who gets treated and who does not.

Introducing practical frameworks such as the Access Equation, the New Value Triangle, and the Access Maturity Matrix, the book equips organisations to move from approval first thinking to access first design, using case studies, leadership tools, and candid reflection to demonstrate how innovation can be built for adoption rather than hope.

For leaders in pharma, biotech, policy, and healthcare, this is both a strategic guide and a moral argument, grounded in a simple truth: the real measure of innovation is not what is approved, but who it ultimately reaches.